Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

References

• Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–881.
   PubMed Web of Science ®Google Scholar
• Haag GM, Zoernig I, Hassel JC, et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoral immune response to NY-ESO-1. Eur J Cancer. 2018;90:122–129.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225–6231.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert Opin Ther Pat. 2019;29(5):311–314.
   PubMed Web of Science ®Google Scholar
• Perez SA, Anastasopoulou EA, Tzonis P, et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother. 2013;62(10):1599–1608.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-γ–mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540–3551.
   PubMed Web of Science ®Google Scholar
• Herrera-Camacho I, Anaya-Ruiz M, Perez-Santos M, et al. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opin Ther Pat. 2019;29(8):587–593.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2017;20(5):674–686.
   Web of Science ®Google Scholar
• Triebel F, Brignone C Combined preparations for the treatment of cancer or infection. United States US 2018271940. 2018 Sep 27.
   Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. LAG-3 antagonists by cancer treatment: a patent review. Expert Opin Ther Pat. 2019;29(8):343–351.
   Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26(6):923–937.
   PubMed Web of Science ®Google Scholar
• Wang M, Bu J, Zhou M, et al. CD8+ T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 2018;190:64–73.
   PubMed Web of Science ®Google Scholar
• Liu XG, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46(2):172–182.
   PubMed Web of Science ®Google Scholar
• Dupont J, Parmar H Oncomed Pharmaceuticals Inc., USA. Methods for treatment of cancer comprising TIGIT-binding agents. International patent WO2018102536. 2018 Jun 7.
   Google Scholar
• Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11(9):1307–1326.
   PubMed Web of Science ®Google Scholar
• Cattaruzza F, Yeung P, Wang M, et al. Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017; 77(13Suppl):Abstract nr 599.
   Google Scholar
• Williams SMG, Seghezzi W, Fayadat-Dilman L, et al., Merck Sharp & Dohme, USA. Anti-TIGIT antibodies. United States patent US2018371083. 2018 Dec 27.
   Google Scholar
• Mandelboin O, Kaynan NS, Tsukerman P, et al., Hebrew University of Jerusalem Ltd. & University of Rijeka. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT). United States patent US2018185480. 2018 Jul 5.
   Google Scholar
• Tso JY, Tsurushita N, Duramad O, JN Biosciences LLC & Abmuno Therapeutics LLC. Antibodies to TIGIT. United States patent US2017281764. 2017 Oct 5.
   Google Scholar
• Maurer MF, Chen TT, Devaux B, et al., Bristol-Myers Squibb Company. Antibodies to TIGIT. United States US10189902. 2019 Jan 29.
   Google Scholar
• Tian Z, Cao G, Wang B, et al., Hefei ruida immune drugs research institute Co Ltd. Antibody or antigen binding fragment capable of being bonded with TIGIT and use thereof. China patent CN109384846. 2019 Feb 26.
   Google Scholar
• Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother. 2018;67(11):1659–1667.
   PubMed Web of Science ®Google Scholar
• Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updat. 2019;45:13–29.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03119428, A study of OMP-313M32 in subjects with locally advanced or metastatic solid tumors, [about 5 screens], Bethesda (MD): National Library of Medicine (US). Dec 7, 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03119428?term=TIGIT&cond=cancer&rank=1
   Google Scholar